TEIJIN GROUP

About Us

Regenerative medicine business of Teijin Group

Teijin Group's purpose is "Pioneering solutions together for a healthy planet", and we will achieve our Long-Term Vision: "To be a company that supports the society of the future" by being a company that prioritizes the health of the planet, protects the environment, and supports a circular society, as well as resolve issues for patients, families, and communities in need of greater support.

In accordance with the commitment, TEIJIN group offers Contract Development and Manufacturing Organization (CDMO) services through the group companies “TEIJIN REGENET Co., Ltd.” and “Japan Tissue Engineering. Co., Ltd. (J-TEC)”. TEIJIN REGENET and J-TEC specialize in cell and gene therapies including tissue-engineered products, with the aim of supporting the process development and manufacturing of cell and gene therapy products in Japan - taking innovative science from concept to patient treatment.

TEIJIN CDMO's strength

One-stop solution to realize the seeds of cell & gene therapy/regenerative medicine

"Kashiwa-no-ha Facility", CDO site of TEIJIN REGENET

• "Kashiwa-no-ha Facility" serves as a core manufacturing function in Kashiwa-no-ha regenerative medicine platform in collaboration with National Cancer Center, Mitsui-Fudosan, and J-TEC. This platform provides one-stop service from early research and development to manufacturing of clinical supply and business strategy with seed holders of cell and gene therapy/regenerative medicine, so that we can contribute to producing innovative medical solutions for the diseases with unmet medical needs.
• The site is adjacent to the National Cancer Center East Hospital and it enables to provide geographical and functional benefits for the R&D consortium.

"Iwakuni Factory", CMO site of TEIJIN REGENET

• "Iwakuni Factrory" provide the integrated manufacturing services through the seamless linkage with Kashiwa-no-ha Facility, from scale-up/scale-out of clinical supply manufacturing to commercial supply manufacturing. We can support various needs of manufacturing such as gene transduction, mass-scale cell culture, and tissue culture.
• We TEIJIN have experience in developing unique pharmaceuticals and medical devices in-house, establishing high-quality production technologies, and commercial supply chain in Japan and overseas. We provide commercial manufacturing services by fully utilizing well established know-hows.

Regulatory approval of the five regenerative medicine products, the largest number in Japan (4 products are on the market) *As of April 2024

• As a pioneer in regenerative medicine, we have cultivated our capability of development, production, and sales, and established the mutual trust relationships of with the regulatory authorities in Japan through the approvals of the multiple products.
• Of the 20 regenerative medicine products in Japan, J-TEC has been making 5 regulatory approvals, including the first and second regenerative medical products in Japan. This is the highest number of achievements of regulatory approvals (of 4 are launched) in Japan.

Supports of vector manufacturing and overseas clinical trials

• Through business alliances with TFBS Bioscience, Inc. (Taiwan) and Mediridge Co., Ltd.(Japan), we support viral vector manufacturing, supply, and related testing services. This collaboration enables to accelerate development of ex vivo gene therapy products.
• Through the alliance with National RESILIENCE, Inc. (United States), we can utilize their global manufacturing platform and support manufacturing of the products for global market expansion.